Research programme: inflammation therapeutics - Evotec/Interprotein
Latest Information Update: 06 Jan 2010
At a glance
- Originator Evotec AG; Interprotein Corporation
- Class Small molecules
- Mechanism of Action Interleukin 6 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Inflammation
Most Recent Events
- 25 Nov 2009 This programme is in active development